The MET inhibitor, capmatinib, is being analyzed as a potential first-line treatment for previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14)-mutated non-small cell lung cancer (NSCLC).
METex14 mutations occur in 3%-4% of newly diagnosed advanced NSCLC cases.
GEOMETRY mono-1 phase II study in which the overall response rate was 67.9% and 40.6% among treatment-naïve and previously treated patients, respectively.
Even more, median duration of response was 11.14 months in treatment-naïve patients and 9.72 months in previously treated patients.
Adverse events include: peripheral edema (42%), nausea (33%), creatinine increase (20%), vomiting (19%), fatigue (14%), decreased appetite (13%), and diarrhea (11%).